This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Gold, P. Articles by Shuster, J. Search for Related Content PubMed PubMed Citation Articles by Gold, P. Articles by Shuster, J.

Physicochemical Approach to the Purification of Human ₁-Fetoprotein from the Ascites Fluid of a Hepatoma-bearing Patient¹

Division of Clinical Immunology and Allergy [P. G., S. O. F., J. S.] and McGill University Medical Clinic, Montreal General Hospital Research Institute [P. G., A. L., H. C. G. W., S. O. F., J. K., J. S.], Montreal, Quebec H3G 1A4, Canada

A method for the purification of human ₁-fetoprotein from the ascites fluid of a hepatoma-bearing patient is described that is capable of yielding large quantities of pure ₁-fetoprotein within a relatively short period of time. The technique is based entirely on the physicochemical properties of the ₁-fetoprotein molecule and uses sequential purification steps: ion-exchange chromatography on DEAE-Sephadex A-50, molecular-sieve chromatography on Sephadex G-200, negative-affinity chromatography on Sepharose-Blue Dextran, positive-affinity chromatography on concanavalin A-Sepharose and, finally, molecular-sieve chromatography on Sephadex G-100. The efficiency of the entire procedure in its present form is 15% of the ₁-fetoprotein activity of the starting preparation from ascites fluid. The purity of the final product was shown by polyacrylamide gel electrophoresis, radioimmunoelectrophoresis, and determinations of the NH₂-terminal and COOH-terminal amino acid residues of the ₁-fetoprotein isolated. Amino acid analysis of the final product revealed a composition very similar to those reported for -fetoprotein preparations that have been previously isolated by the use of immunochemical technology.

¹ This investigation was supported by grants from the Medical Research Council of Canada, Ottawa, Ontario, Canada, and the National Cancer Institute of Canada, Toronto, Ontario, Canada.

² Associate of the Medical Research Council of Canada.

³ Clinical Research Associate of the National Cancer Institute of Canada.

Received 12/20/76. Accepted 9/27/77.